Fig. 2From: Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in ChinaTornado analysis (ICER). Cost per additional quality-adjusted life year (bars) of rivaroxaban compared to adjusted-dose warfarin as determined in tornado diagram over plausible ranges for all variables. The willingness-to-pay threshold of 202295.67 yuan per quality-adjusted life year are presented.Back to article page